When treated with etrasimod, patients with ulcerative colitis (UC) achieved symptomatic improvement as early as day 2, Marla Dubinsky, MD, stated in her oral paper presentation at the American College of Gastroenterology Scientific Meeting on October 24 in Vancouver, Canada

Dr Dubinsky is a professor of pediatrics and medicine, and chief of the pediatric gastroenterologist division at Mount Sinai Kravis Children’s Hospital in New York. She is also the co-director of the Susan and Leonard Feinstein Clinical IBD Center.

“What was shown already and published was the efficacy and safety of etrasimod in both ELEVATE UC 52 and ELEVATE UC 12,” Dr Dubinsky said. “More patients treated with etrasimod versus placebo achieved clinical remission and response during the 12-week induction period for both ELEVATE UC 52 and ELEVATE UC 12.”

For the phase 3 clinical trial, Dubinsky et al collected rectal bleeding and stool frequency data from 787 patients with moderate to severe UC enrolled in both ELEVATE UC 52 and ELEVATE UC 12. They randomly assigned etrasimod 2 mg to 527 patients and placebo to 260 patients.

Across both the groups, mean rectal bleeding scores were 1.6 and mean stook frequency scores were 2.4. Mean partial modified Mayo score (pMMS) was 4 for both etrasimod and placebo groups.

According to the results, “16.83% of patients in the etrasimod group achieved symptomatic response by day 2 vs. 11.16% in the placebo group,” Dr Dubinsky excplained. “Additionally, 13.59% of the patients treated with etrasimod achieved symptomatic remission compared to 8.71% of the patients in the placebo group.”

“These findings suggest that etrasimod has a rapid treatment effect with early symptomatic response,” Dr Dubinsky concluded.

Etrasimod is an investigational, oral, once-daily, selective sphingosine 1‑phosphate receptor modulator in development for the treatment of moderately to severely active UC.

Reference:
Dubinsky M. 33 - Symptomatic improvement observed within 2 days of etrasimod induction therapy: Results from ELEVATE UC 52 and ELEVATE UC 12 studies in patients with ulcerative colitis. Presented at: 2023 ACG Scientific Meeting. Vancouver, Canada. October 24, 2023